| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825072 | Clinical Therapeutics | 2014 | 20 Pages |
Abstract
The steady state pharmacokinetics of setrobuvir appear to be dose proportional, and setrobuvir produces a mean reduction of 2.9 log10 IU/mL in HCV RNA over 3 days in patients with genotype 1 (a and b) treated with 800 mg BID. ClinicalTrials.gov identifier: NCT00782353
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Navita L. PhD, Mohamad H. PhD, Constance A. BSc, James R. PhD, Patrick F. PharmD, James L. MD,